Suzana Nesi Nesi França

Dr. Suzana Nesi Nesi França

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Revista Paulista de Pediatria
Verified
Journal Article
Open access
PDF file
LSLeonardo Calil Vicente Franco de Souza
Leonardo Calil Vicente Franco de Souza
GKGabriela de Carvalho Kraemer
Gabriela de Carvalho Kraemer
AKAdriana Koliski
Adriana Koliski
JCJOSE EDUARDO CARREIRO
JOSE EDUARDO CARREIRO
MCMônica Nunes Lima Cat
Mônica Nunes Lima Cat
SFSuzana Nesi Nesi França
Suzana Nesi Nesi França
Objective: To analyze the variables associated with the presence of diabetic ketoacidosis in type 1 diabetes mellitus (T1DM) diagnosis and its impact on the progression of the disease. Methods: We reviewed the records of 274 children and adolescents under 15 years, followed in a Pediatric Endocrinology clinic of a university hospital in Curitiba-PR. They had their first appointment between January 2005 and April 2015. Results: Most patients received their T1DM diagnosis during a diabetic ketoacidosis episode. The associated factors were: lower age and greater number of visits to a physician’s office prior to diagnosis; diabetic ketoacidosis was less frequent in patients who had siblings with T1DM and those diagnosed at the first appointment. Nausea and vomiting, abdominal pain, tachydyspnea, and altered level of consciousness were more common in the diabetic ketoacidosis group. There was no association with socioeconomic status, duration of symptoms before diagnosis, and length of the honeymoon period. Conclusions: Prospective studies are necessary to better define the impact of these factors on diagnosis and disease control. Campaigns to raise awareness among health professionals and the general population are essential to promote early diagnosis and proper treatment of diabetes mellitus in children and adolescents.

27 June 2022 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
VLValderi de Abreu de Lima
Valderi de Abreu de Lima
FMFrancisco José de Menezes
Francisco José de Menezes
LCLuana da Rocha Celli
Luana da Rocha Celli
SFSuzana Nesi Nesi França
Suzana Nesi Nesi França
GCGabriel Ribeiro Cordeiro
Gabriel Ribeiro Cordeiro
NLNeiva Leite
Neiva Leite
Resistance training has shown the potential to contribute to better glycemic control in people with Type 1 Diabetes (T1D), however, there are contradictory results in this regard and a need to clarify the effects of isolated resistance training on glycemic control in T1D. The aim was to verify the effects of resistance training on the glycemic control of people with T1D. Original articles were selected, randomized and non-randomized clinical trials that aimed to verify chronic responses, through the concentrations [...] ABSTRACT Resistance training has shown the potential to contribute to better glycemic control in people with Type 1 Diabetes (T1D), however, there are contradictory results in this regard and a need to clarify the effects of isolated resistance training on glycemic control in T1D. The aim was to verify the effects of resistance training on the glycemic control of people with T1D. Original articles were selected, randomized and non-randomized clinical trials that aimed to verify chronic responses, through the concentrations

1 November 2018 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
KMKarina Andressa Khater Fontes Martins
Karina Andressa Khater Fontes Martins
Luís P. MascarenhasLuís P. Mascarenhas
Luís P. Mascarenhas
MMMelina Morandini
Melina Morandini
MCMonica Nunes Lima Cat
Monica Nunes Lima Cat
RPRosana Marques Pereira
Rosana Marques Pereira
SFSuzana Nesi Nesi França
Suzana Nesi Nesi França
SUMMARY Health-related quality of life (HRQOL) in type 1 diabetes mellitus (T1DM) has been widely studied. The objectives of this study were to evaluate and identify the factors influencing the HRQOL of children and adolescents with T1DM. MATERIAL AND METHODS: In total, 59 patients (9–16 years, T1DM for ≥1 year) responded to a version of the Diabetes Quality of Life Instrument for Youth (DQOLY) adapted to adapted to Brazilian patients, the Instrumento de Qualidade de Vida para Jovens com Diabetes (IQVJD). This instrument comprises 50 items (domains satisfaction, impact, and concerns, with the lowest scores corresponding to better HRQOL) and a questionnaire gathering social, demographic, and clinical parameters. RESULTS: The mean age of the patients was 13.6 years, and 57.6% were girls. The median age at diagnosis was 7.16 years, 63% presented diabetic ketoacidosis (DKA) at diagnosis and 29% during follow-up. Mean glycated hemoglobin (HbA1c) in the previous year was 10%. All patients administered multiple insulin doses (mean 4.2 applications/day), 74.5% used rapid-acting and intermediate-acting insulin analogs, and 67.8% used pens for insulin application. The results of the DQOLY were within the cutoff limit for better HRQOL. An isolated analysis of each domain and the questionnaire results showed that the following factors were associated with better HRQOL: height Z-score, lower HbA1c, practice of physical activity, use of pen, fewer hospitalizations, and residence in a rural area. There was a high DKA rate at diagnosis, and the metabolic control was inappropriate in most patients. Despite coming from low-income households, most patients had access to the recommended treatment. CONCLUSION: Among T1DM patients, 71% had IQVJD scores compatible with better HRQOL.

13 October 2020 in Journal of Pediatric Endocrinology and Metabolism
Verified
Journal Article
Closed access
SFSuzana Nesi Nesi França
Suzana Nesi Nesi França
RSRodrigo B. Silveira
Rodrigo B. Silveira
JRJuliana Cristina R. Rojas Ramos
Juliana Cristina R. Rojas Ramos
ACAdriane de Andre Cardoso-Demartini
Adriane de Andre Cardoso-Demartini
MCMonica N. Lima Cat
Monica N. Lima Cat
LLLuiz De Lacerda
Luiz De Lacerda
Objectives: Adequate treatment of congenital hypothyroidism (CH) is required for normal growth and sexual development. To evaluate pubertal development in patients with permanent CH detected by a statewide Neonatal Screening Program of Paraná and, secondly, to evaluate adult height (AH) in a subgroup of patients. Methods: Clinical, laboratory, and auxological data obtained from medical records of 174 patients (123 girls). Results: Median chronological age (CA) at treatment initiation was 24 days, and mean initial levothyroxine dose was 11.7 ± 1.9 μg/kg/day; mean CA at puberty onset was 11.5 ± 1.3 years (boys) and 9.7 ± 1.2 years (girls); mean CA in girls who underwent menarche (n=81) was 12.1 ± 1.1 years. Thyroid-stimulating hormone (TSH) values above the normal range were observed in 36.4% of the boys and 32.7% of the girls on puberty onset, and in 44.6% around menarche. Among 15 boys and 66 girls who had reached the AH, the median height z-score value was significantly greater than the target height (TH) z-score value in boys (p=0.01) and in girls (p<0.001). Boys with normal TSH values at puberty onset had greater mean AH z-score compared with boys with TSH values above the normal range (p=0.04). Conclusions: In this group, pubertal development in girls with CH was not different from that reported in healthy girls in the general Brazilian population. Boys with higher TSH at puberty onset may have an increased risk of not reaching their potential height compared with those with normal TSH during this period. In a subgroup who attained AH, the median AH z-score was greater than the median TH z-score.

5 June 2020 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
DRDenise Barth Rebesco
Denise Barth Rebesco
SFSuzana Nesi Nesi França
Suzana Nesi Nesi França
VLValderi Abreu de Lima
Valderi Abreu de Lima
NLNeiva Leite
Neiva Leite
LSLeandro Smouter
Leandro Smouter
Luís P. MascarenhasLuís P. Mascarenhas
Luís P. Mascarenhas
Key words: Moderate to vigorous physical activity; glycemic variability; type 1 diabetes mellitus

1 February 2008 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
CPCarla C. Pavan-Senn
Carla C. Pavan-Senn
SFSuzana Nesi Nesi França
Suzana Nesi Nesi França
JPJulita Pelaez
Julita Pelaez
RPRosana M. Pereira
Rosana M. Pereira
MBMargaret C. da S. Boguszewski
Margaret C. da S. Boguszewski
LFLuiz de Lacerda Filho
Luiz de Lacerda Filho
INTRODUÇÃO: A amiodarona (AMD) é uma droga antiarrítmica que contém 37% de iodo. A AMD pode alcançar o feto por via transplacentária e causar hipotireoidismo congênito (HC) ou transitório (HCT). Relatamos dois casos de HCT em virtude de exposição gestacional à AMD, detectados pelo programa de triagem neonatal para HC no Estado do Paraná, Brasil. CASO CLÍNICO 1 (C1): TSH neonatal 78,2 mU/L (normal < 15 mU/L). A AMD foi utilizada durante toda a gestação em virtude de arritmia materna. As dosagens séricas iniciais confirmaram o HC; e na primeira consulta [aos 14 dias de vida (dv)], foi iniciada levotiroxina (L-T4), 50 µg/dia. CASO CLÍNICO 2 (C2): TSH neonatal 134 mU/L. A AMD foi utilizada no último trimestre da gestação em virtude de arritmia materna. As dosagens séricas iniciais confirmaram o HC; aos 13 dv, foi iniciada L-T4 50 µg/dia. ACOMPANHAMENTO: TSH e T4 estavam normais aos 51 dv (C1) e aos 36 dv (C2) sendo então gradativamente reduzida a dose da medicação e suspensa aos 16 meses (C1) e aos dez meses (C2). As pacientes foram acompanhadas até 22 meses (C1) e 16 meses (C2) com testes de função tireoidiana normais. O crescimento e o desenvolvimento neuropsicomotor (DNPM), avaliados pelo teste CAT/CLAMS, eram normais. CONCLUSÃO: As avaliações da função tireoidiana e do DNPM são necessários quando a AMD é utilizada na gestação. O tratamento do HCT deve ser instituído tão logo o diagnóstico seja realizado.